Anthony Fauci called observations made by Republican Senator Ron Johnson. The National Institute of Allergy and Infectious Diseases director responded to assertions by the senator that Fauci overhyped the dreaded AIDS calamity and the present pandemic.
Johnson had made the baseless remarks during a podcast aired on Wednesday, also AIDS Day. He said that Fauci had done exactly the same when AIDS was in the news. He said it was overhyped and said that American officials are using it to create an atmosphere of fear.
Johnson said that Anthony Fauci had created a state of fear by saying that the Coronavirus could touch the whole population though it wasn’t true. He said that Dr. Anthony Fauci was repeating that for COVID-19.
Fauci hit back at the wild comments, saying that he could he had little idea what the Republican Senator was speaking about. He said that it was difficult to reply to such a preposterous statement.
Anthony Fauci Had Been Attacked For Not Starting Clinical Trials Fast Enough During The Aids Epidemic
Fauci said it was difficult to respond to the allegation that he had overhyped AIDS, killing more than 750,000 in the US, and over 36M across the planet. He said that COVID-19 had already killed over 780,000 Americans and over 5M worldwide.
Anthony Fauci said it was difficult to even respond to such statements. He said he had little clue what the Republican Senator was talking about. The host replied that he doubted even Johnson had any idea.
Anthony Fauci is also the chief medical advisor to the President. In an earlier documentary, he has suffered PTSD from heading the American response to AIDS in the last two decades of the past century. He said that the situation alternated between bad and worse all those years.
Anthony Fauci said that it was frustrating when faced with a situation where he could do nothing. Fauci had faced constant attacks from right-wingers during the peak year of AIDS. Then the allegation had been just the reverse. Republicans were up in arms that Anthony Fauci wasn’t acting fast enough then in starting clinical trials.
